$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Ibrutinib/ibrutinib medical insurance price in 2024
2026-02-01 22:25:32
Check Details
Price analysis of ibrutinib/ibrutinib
2026-02-01 22:25:32
Check Details
Who is the manufacturer of ibrutinib/ibrutinib?
2026-02-01 22:25:32
Check Details
Detailed explanation of ibrutinib/ibrutinib 2024 medical insurance pricing and reimbursement
2026-02-01 22:25:32
Check Details
In-depth analysis of the differences between ibrutinib/ibrutinib and zanubrutinib
2026-02-01 22:25:32
Check Details
Efficacy and effects of ibrutinib/ibrutinib
2026-02-01 22:25:32
Check Details
What are the side effects of ibrutinib/ibrutinib?
2026-02-01 22:25:32
Check Details
What diseases does ibrutinib/ibrutinib capsules mainly treat?
2026-02-01 22:25:32
Check Details
Usage and dosage of ibrutinib/ibrutinib capsules
2026-02-01 22:25:32
Check Details
How many years can you live taking ibrutinib/ibrutinib?
2026-02-01 22:25:32
Check Details
Ibrutinib/ibrutinib capsules treat various lymphoid and blood cancers
2026-02-01 22:25:32
Check Details
Unique efficacy of ibrutinib/ibrutinib in the treatment of B-cell lymphoma
2026-02-01 22:25:32
Check Details
1
2
...
637
638
639
640
641
642
643
...
10222
10223
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
FDA Approves Lytenava: First Ophthalmic Bevacizumab for Wet AMD
2
Simtriyo (Centanafadine): World's First NDSRI ADHD Drug Approved by FDA
3
Lipfendra (Enlicitide): The World's First Oral PCSK9 Inhibitor Approved by FDA
4
Orforglipron: The World's First Oral Small-Molecule GLP-1 Receptor Agonist for Weight Management
5
Cabozantinib Capsules: A Multi-Targeted Therapy for Progressive Medullary Thyroid Cancer
6
Lorlatinib: Mechanism, Advantages, and Key Considerations of Third-Generation ALK Inhibitor Therapy in ALK-Positive NSCLC
7
FDA Approves Subcutaneous Isatuximab (Sarclisa) for Multiple Myeloma: A New Administration Option
8
Pemigatinib Side Effects Explained: Managing Adverse Reactions of FGFR-Targeted Therapy in Cholangiocarcinoma
9
Selpercatinib: Before or After Meals? A Complete Guide to RET-Targeted Therapy Administration
10
Mitotane for Adrenocortical Carcinoma: Dosing Guidelines and Therapeutic Drug Monitoring
11
Vadadustat: Clinical Evidence and Patient Benefits of an Oral HIF-PHI for CKD-Related Anemia
12
Ponatinib vs. Olverembatinib: A Multidimensional Comparison of Third-Generation BCR-ABL Inhibitors